华北制药：下属公司头孢丙烯片获得《药品注册证书》

Core Viewpoint - North China Pharmaceutical (600812.SH) announced that its wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., has received the drug registration certificate for Cefprozil tablets (0.25g) from the National Medical Products Administration, indicating a significant regulatory approval for a new antibiotic product [1] Group 1: Product Approval - The drug Cefprozil is classified as a second-generation cephalosporin antibiotic [1] - The approved indications for Cefprozil in China include treatment for mild to moderate infections caused by sensitive bacteria, such as upper respiratory infections, lower respiratory infections, and skin and soft tissue infections [1] Group 2: Indications - For upper respiratory infections, Cefprozil is indicated for conditions like streptococcal pharyngitis/tonsillitis and acute otitis media caused by Streptococcus pneumoniae and Haemophilus influenzae [1] - In lower respiratory infections, it is used for acute bronchitis secondary to bacterial infections and acute exacerbations of chronic bronchitis [1] - The drug is also indicated for non-complicated skin and soft tissue infections caused by Staphylococcus aureus and streptococci, although abscesses typically require surgical drainage [1]